Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2017 1
2018 1
2021 2
2022 3
2023 6
2024 5
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
A pan-cancer analysis of the microbiome in metastatic cancer.
Battaglia TW, Mimpen IL, Traets JJH, van Hoeck A, Zeverijn LJ, Geurts BS, de Wit GF, Noë M, Hofland I, Vos JL, Cornelissen S, Alkemade M, Broeks A, Zuur CL, Cuppen E, Wessels L, van de Haar J, Voest E. Battaglia TW, et al. Among authors: vos jl. Cell. 2024 Apr 25;187(9):2324-2335.e19. doi: 10.1016/j.cell.2024.03.021. Epub 2024 Apr 9. Cell. 2024. PMID: 38599211 Free article.
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.
Yoo SK, Fitzgerald CW, Cho BA, Fitzgerald BG, Han C, Koh ES, Pandey A, Sfreddo H, Crowley F, Korostin MR, Debnath N, Leyfman Y, Valero C, Lee M, Vos JL, Lee AS, Zhao K, Lam S, Olumuyide E, Kuo F, Wilson EA, Hamon P, Hennequin C, Saffern M, Vuong L, Hakimi AA, Brown B, Merad M, Gnjatic S, Bhardwaj N, Galsky MD, Schadt EE, Samstein RM, Marron TU, Gönen M, Morris LGT, Chowell D. Yoo SK, et al. Among authors: vos jl. Nat Med. 2025 Mar;31(3):869-880. doi: 10.1038/s41591-024-03398-5. Epub 2025 Jan 6. Nat Med. 2025. PMID: 39762425 Free PMC article.
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, Lubeck Y, Seignette IM, Smit LA, Willems SM, van den Brekel MWM, Dirven R, Baris Karakullukcu M, Karssemakers L, Klop WMC, Lohuis PJFM, Schreuder WH, Smeele LE, van der Velden LA, Bing Tan I, Onderwater S, Jasperse B, Vogel WV, Al-Mamgani A, Keijser A, van der Noort V, Broeks A, Hooijberg E, Peeper DS, Schumacher TN, Blank CU, de Boer JP, Haanen JBAG, Zuur CL. Vos JL, et al. Nat Commun. 2021 Dec 22;12(1):7348. doi: 10.1038/s41467-021-26472-9. Nat Commun. 2021. PMID: 34937871 Free PMC article. Clinical Trial.
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.
Vos JL, Burman B, Jain S, Fitzgerald CWR, Sherman EJ, Dunn LA, Fetten JV, Michel LS, Kriplani A, Ng KK, Eng J, Tchekmedyian V, Haque S, Katabi N, Kuo F, Han CY, Nadeem Z, Yang W, Makarov V, Srivastava RM, Ostrovnaya I, Prasad M, Zuur CL, Riaz N, Pfister DG, Klebanoff CA, Chan TA, Ho AL, Morris LGT. Vos JL, et al. Nat Med. 2023 Dec;29(12):3077-3089. doi: 10.1038/s41591-023-02518-x. Epub 2023 Aug 24. Nat Med. 2023. PMID: 37620627 Free PMC article. Clinical Trial.
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.
Breukers SE, Traets JJH, van Dijk SW, Ostos MM, Fraterman I, Crommelin RD, van der Hulst H, Qiao X, Boere T, van de Poll-Franse LV, Retèl V, van der Noort V, Vos JL, Toppenberg AGL, van der Heijden M, Missale F, Balm F, van den Brekel M, Dirven R, Karakullukcu MB, Karssemakers L, Klop WMC, Lohuis PJFM, Schreuder WH, Smeele LE, van der Velden LA, Plasmeijer E, Smit LA, de Boer JP, Navran A, Westerink B, de Koekkoek-Doll PK, Castelijns J, Wondergem M, Vogel WV, Kuijpers A, van Houdt WJ, Onderwater S, Maas-Bannink E, Cornelissen S, Broeks A, Tijink BM, Devriese LA, de Bree R, Blank CU, Schumacher TN, Thommen DS, Haanen JBAG, Zuur CL. Breukers SE, et al. Among authors: vos jl. Nat Med. 2025 Dec;31(12):4055-4064. doi: 10.1038/s41591-025-03943-w. Epub 2025 Oct 8. Nat Med. 2025. PMID: 41062829 Free PMC article. Clinical Trial.
Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma.
Desilets A, Vos JL, Katabi N, Kuo F, Nadeem Z, Linxweiler M, Ostrovnaya I, Baxi S, Dunn LA, Sherman EJ, Pfister DG, Morris LGT, Ho AL. Desilets A, et al. Among authors: vos jl. Clin Cancer Res. 2024 Dec 2;30(23):5281-5292. doi: 10.1158/1078-0432.CCR-24-1064. Clin Cancer Res. 2024. PMID: 39352719 Free PMC article. Clinical Trial.
Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.
Vos JL, Traets JJ, Qiao X, Seignette IM, Peters D, Wouters MW, Hooijberg E, Broeks A, van der Wal JE, Karakullukcu MB, Klop WMC, Navran A, van Beurden M, Brouwer OR, Morris LG, van Poelgeest MI, Kapiteijn E, Haanen JB, Blank CU, Zuur CL. Vos JL, et al. JCI Insight. 2024 Nov 8;9(21):e179982. doi: 10.1172/jci.insight.179982. JCI Insight. 2024. PMID: 39513365 Free PMC article.
CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors.
Lei X, de Groot DC, Welters MJP, de Wit T, Schrama E, van Eenennaam H, Santegoets SJ, Oosenbrug T, van der Veen A, Vos JL, Zuur CL, de Miranda NFCC, Jacobs H, van der Burg SH, Borst J, Xiao Y. Lei X, et al. Among authors: vos jl. Cell Mol Immunol. 2024 Apr;21(4):374-392. doi: 10.1038/s41423-024-01133-1. Epub 2024 Feb 21. Cell Mol Immunol. 2024. PMID: 38383773 Free PMC article.
23 results